IMU 5.77% 5.5¢ imugene limited

Media Thread, page-13931

  1. 27,040 Posts.
    lightbulb Created with Sketch. 1748
    IMU has already presented HER-Vaxx data for end of Ph2 clinical trial last month and is too expensive to conduct Ph3 given their current cash balance and MC. PH seems to be trying to get the other IP to end of Ph2 or at a stage which will attract BP to sell the lot. I think BP will act early on VAXINIA and onCARlytics at end of Ph1 in 6-9 months time instead of waiting for near or end of Ph2 especially for VAXINIA as it's already demonstrate efficacy which is the primary end point for Ph2.

    CMO changes whenever the development stage of the IP changes and IMU has been moving very quickly in their development stage for their multiple platform, there's a synergy between CF33, onCARlytics and Azer-Cel (hence the acquisition 8 months ago) which LC has mentioned.
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
5.5¢
Change
0.003(5.77%)
Mkt cap ! $404.2M
Open High Low Value Volume
5.2¢ 5.7¢ 5.2¢ $802.5K 14.79M

Buyers (Bids)

No. Vol. Price($)
1 348447 5.4¢
 

Sellers (Offers)

Price($) Vol. No.
5.5¢ 1214875 6
View Market Depth
Last trade - 16.10pm 09/08/2024 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.